Most material SEC filings — August 10, 2026

On April 24, 2026, Pioneer Bank (subsidiary of Pioneer Bancorp, Inc., $121.4M market cap) acquired 100% of Targeted Lending Co., LLC for total consideration of ~$124.4M, comprising $122.8M cash and $1.6M contingent consideration. Targeted Lending is an equipment finance company with $104.2M in loans receivable, $83.2M total liabilities, and $21.7M equity as of Dec 31, 2025. The acquisition triggered $15.7M goodwill and $9.3M intangible assets (customer relationships, technology). Financing via brokered deposits.

AbbVie agreed in June 2026 to acquire all outstanding Apogee shares for $135.11 per share in cash, totaling approximately $10.9 billion in equity value. The transaction is expected to close in Q3 2026, subject to shareholder approval and regulatory clearance. Concurrently, Apogee received $1.3 billion in non-dilutive financing from Blackstone Life Sciences in May 2026 to fund Phase 3 development of zumilokibart; the company reported positive Phase 2 APEX Part B results (65.9% EASI-75 response at mid-dose) supporting planned Phase 3 advancement in atopic dermatitis.

Cherry Hill Mortgage Investment Corp (market cap ~$97.4M) agreed to merge into TPG Mortgage Investment Trust, Inc. (Parent). Company shareholders receive 0.3063 Parent common shares per Company share plus $0.41 cash per share plus $0.52 additional cash consideration from Parent Manager. Preferred shareholders receive one-for-one conversion into Parent's new preferred series (D and E). Agreement dated August 9, 2026; merger consideration includes equity exchange and modest cash component.

On August 9, 2026, TPG Mortgage Investment Trust (MITT) agreed to acquire Cherry Hill Mortgage Investment Corp in an all-stock-and-cash deal valued at $117.5 million ($3.10/share), representing a 29% premium to Cherry Hill's closing price on August 7, 2026. Each Cherry Hill common shareholder will receive 0.3063 MITT shares plus $0.93 cash per share. The transaction is expected to close in Q4 2026, subject to stockholder approval and customary conditions. Cherry Hill's Q2 2026 results showed GAAP net income of $1.3 million ($0.04/share) and EAD of $5.5 million ($0.15/share), with book value of $3.16/share and 5.02x leverage.

SHM Holdco LLC (Blackstone-backed) agreed to acquire MarineMax Inc. for $53.00 per share in an all-cash transaction. Based on 22,086,735 outstanding shares as of August 6, 2026, the total equity consideration is approximately $1.17 billion. Blackstone Infrastructure Partners L.P. committed equity financing. Closing is expected after December 7, 2026, subject to shareholder approval and regulatory clearances.

On August 7, 2026, INNOVATE Corp. (Parent) agreed to be acquired by IES Holdings, Inc. (Buyer) via merger. Buyer will acquire all shares of DBM Global, Inc. (the Company) held by Parent and DBM Global Intermediate Holdco Inc. for Stock Consideration (shares of IES common stock, number unspecified in filing excerpt) and Seller Cash Consideration (amount unspecified). The transaction includes a $35M payment to Seller at Closing for tax election cooperation. Closing is contingent on regulatory approvals, HSR clearance, and other standard conditions.

Bowman Consulting Group Ltd. agreed to be acquired by Prive Parent, Inc. (backed by BCP funds) for $43.00 per share in cash, valuing the company at approximately $745 million (17.33M shares × $43). The transaction includes assumption of company debt and payment of equity awards. Closing is expected following HSR clearance and stockholder approval, with a termination date currently set for August 10, 2027 (one year). Prive is backed by equity commitments from BCP Fund III entities and debt financing from undisclosed lenders.

Aspire Biopharma (market cap ~$17.4M) completed acquisition of Dura Driver Control Systems (DCS) for ~$30M cash on August 10, 2026. DCS generated $209.5M revenue and $22.3M Adjusted EBITDA in 2025 (H1 2026: $103.9M revenue, $10.5M EBITDA). Aspire also secured $22.5M senior revolving credit facility. Simultaneously, Aspire raised $3M via convertible notes at 20% OID, $8.00 conversion price, 6-month maturity, with registration rights and liquidated damages for registration delays.

Teledyne Technologies agreed to acquire Varex Imaging Corporation (NASDAQ: VREX) for $18.90 per share in an all-cash merger. The transaction values Varex at approximately $799.4 million (42.15M shares × $18.90), with Varex shareholders receiving cash consideration upon closing. Teledyne will merge a wholly-owned subsidiary into Varex, with Varex becoming a Teledyne subsidiary. Closing is expected by May 10, 2027, subject to regulatory approvals including HSR and other governmental consents.

On August 4, 2026, Lexaria Bioscience Corp. received notice of delisting or failure to satisfy continued listing standards. The specific grounds, timeline, and remediation options are not detailed in this filing excerpt. This represents a critical corporate event for a $24.6M market-cap company.

Neptune BidCo US Inc. agreed to acquire DoubleVerify Holdings, Inc. in an all-cash merger dated August 6, 2026. Merger consideration is $13.60 per share. Elliott Associates and Elliott International guarantee certain Parent obligations under a limited guarantee. Equity and debt financing commitments support the transaction; closing conditioned on stockholder approval, regulatory clearances, and other customary conditions.

On June 29, 2026, Theravance Biopharma announced a definitive acquisition agreement with Zymeworks Inc. at $17.00 per share in cash, plus a contingent value right (CVR) entitling shareholders to 80% of net proceeds from future ampreloxetine monetization over ten years. Transaction expected to close H2 2026 subject to shareholder approval. Company reported Q2 2026 revenue of $20.7M (11% YoY growth), $387.7M cash, no debt, and 35% YoY reduction in operating expenses.

Verb Technology (operating as TON Strategy Co) engaged Kingsway Capital Partners Limited effective August 7, 2025, to advise on cryptocurrency and digital asset integration into treasury management. Compensation: $3 million one-time setup fee (payable within 5 business days in Toncoin or cash) plus annual advisory fee of 2% of market capitalization paid monthly. 20-year initial term with annual renewals; either party may terminate with 60 days' written notice for material breach.

On August 10, 2026, Penske Automotive Group's independent special committee retained Moelis & Company as financial advisor and Paul, Weiss as legal counsel to evaluate an unsolicited, non-binding proposal from Penske Corporation and Mitsui & Co., Ltd. to acquire all remaining shares at $210 per share in cash. The proposal was received July 22, 2026; no agreement is assured, and the company will not comment further unless disclosure is deemed appropriate or required.

Chief Executive Officer Huang Jack Jiajia (COE) bought 741K shares (~$13.8M) on the open market (2.1% of holdings). Open-market insider purchase — historically a bullish signal.

TPG Mortgage Investment Trust (Parent, $214.4M market cap) agreed to acquire Cherry Hill Mortgage Investment Corporation (Company) in a two-step merger effective August 9, 2026. Company shareholders receive 0.3063 Parent shares per Company Common Stock plus $0.41 cash per share, plus $0.52 per share from Parent Manager. Company Series A Preferred converts 1:1 to Parent Series D; Series B Preferred converts 1:1 to Parent Series E. Company Termination Fee: $4.7M; Parent Termination Fee: $7.99M. Combined entity will operate as single REIT.

On August 7, 2026, Yorkville Acquisition Corp. (SPAC), its subsidiary YA S3 Inc., Trump Media Technology Group Corp., Crypto.com, and their respective entities mutually terminated the Business Combination Agreement dated August 25, 2025 (as amended October 31, 2025) to establish Trump Media Group CRO Strategy, Inc. The termination was effective immediately with mutual written consent under Section 9.1(a) of the BCA. All parties released each other from claims arising from the BCA and ancillary documents. Additionally, Crypto.com, Trump Media, and Yorkville America mutually agreed not to pursue their previously announced ETF servicing partnership, though Yorkville America's existing ETF business remains unchanged. No termination fee is due from any party.

As of August 9, 2026, Bitmine holds 5.81 million ETH (4.8% of total 120.7M ETH supply) valued at ~$11.2B at $1,928/token, plus $104M cash and $249M in other crypto/equity stakes, totaling $11.6B. Since July 1, 2026, the company repurchased 19.1 million common shares under a $4B program; 3 million shares repurchased in the past week alone. Staked ETH of 5.07 million generates annualized staking revenue of ~$257M ($294M at full scale). The company claims #1 global ETH treasury and #2 overall crypto treasury status.

Arts Way Manufacturing's Modular Buildings segment was awarded major projects increasing backlog to $19.0 million as of August 10, 2026, versus $1.3 million reported in the Q1 2026 10-Q (ended May 31, 2026). The backlog represents a 1,362% increase and is expected to be substantially fulfilled by end of fiscal 2027. Customer identities remain confidential; margins expected consistent with historical Modular Buildings performance.

Vera Therapeutics received FDA accelerated approval for TRUTAKNA (atacicept-vymj) in June 2026 for adult IgAN patients at risk for disease progression, based on 46% proteinuria reduction vs. placebo at 36 weeks. The company has aligned with FDA on an earlier ORIGIN 3 final efficacy analysis expected Q3 2026, with sBLA submission anticipated Q4 2026 and potential full approval in 2027. Q2 2026 net loss was $109.5M (vs. $76.5M in Q2 2025); cash on hand is $499.2M plus $425M available debt facility.

ARK Restaurants reported Q3 2026 revenues of $40.9M (down 6.6% YoY from $43.7M); 39-week revenues down 7.2% to $118.2M from $128.4M. Net loss for Q3 was $347K ($0.10/share) vs. $3.5M loss prior year. Critical: Bryant Park Grill/Café/Porch locations (14.5% of 39-week revenues = $17.1M) face court-ordered eviction around October 16, 2026, unless appeal succeeds or stay extends. Company posted $125K undertaking July 21, 2026, and continues monthly occupancy payments. Additionally, New Jersey gaming referendum for Meadowlands Racetrack investment delayed to 2027 at earliest, creating valuation uncertainty.

GoPro reported Q2 2026 revenue of $105 million, down 31% year-over-year from $152.6 million in Q2 2025, with hardware revenue falling 39.9% to $75.9 million and camera unit sell-through declining 38% to ~291,000 units. The company posted a GAAP net loss of $51 million ($(0.30)/share) versus $(16.4)M in Q2 2025, and adjusted EBITDA deteriorated to $(29.5)M from $(5.7)M. In May 2026, GoPro's Board authorized a strategic review to evaluate a potential sale and other alternatives to maximize shareholder value. Positive offset: subscription revenue grew 11% YoY to $29 million with a record 69% attach rate (up from 54%), and direct-to-consumer revenue rose 13% YoY.

USA Rare Earth announced definitive agreements with U.S. Department of Commerce for up to $1.6 billion in funding ($277M grants + $1.3B senior secured loans under CHIPS Act, milestone-based). The company agreed to acquire 100% of Serra Verde Group (Pela Ema mine, Brazil) for ~$2.8 billion, securing the only large-scale HREE producer outside Asia with a 15-year offtake agreement. Additional moves: 13.6% stake in French processor Carester, commissioning of Colorado hydrometallurgical facility, new South Carolina magnet/metals plant targeting 2028 commissioning (490 jobs), and CEO transition to Serra Verde's Thras Moraitis effective October 2026. Q2 2026 revenues $5.8M; cash position $1.53B after $1.5B PIPE raise.

ClearOne Inc (market cap ~$5.1M) filed an S-1 to raise $10–15M (minimum–maximum) via best-efforts offering of 2.86–4.29M units at $3.50/unit (1 share + 1 warrant at $10.00 strike, 6-month expiry). Proceeds fund: Cortigent neurostimulation R&D ($2M), First Finance Ltd. loan repayment ($1.1M), Orion pivotal trial prep ($1M), device manufacturing ($4M), merger expenses & working capital (remainder). Merger: ClearOne acquires Cortigent (subsidiary of Vivani Medical) for 12.5M shares; Vivani sole shareholder; closing contingent on financing completion and Nasdaq approval. First Finance Ltd. controls ~61% pre-offering, will invest $1M this round.

LQR House Inc. acquired a controlling interest (54%) in Fusion Five Continents Securities Limited through two closings: 24% for $28.08M (April 24, 2026) and 30% for $39M (June 1, 2026), totaling $67.08M in USDT. The acquisition agreement contemplates up to $126.88M total for all 100% ownership. Fusion Five is a New Zealand-registered cross-border securities broker offering Hong Kong and U.S. equity trading via USDT settlement; it reported $20,561 revenue and $74,562 net loss for the year ended March 31, 2026, with going-concern doubt alleviated post-acquisition. LQR financed the second closing with $40M in unsecured notes at 6% due May 2028.

10% owner DART KENNETH BRYAN (FLUT) bought 500K shares (~$46.4M) on the open market (2.3% of holdings). Open-market insider purchase — historically a bullish signal.

NeOnc (market cap ~$67.9M) reported Q2 2026 results: net loss $14.2M ($0.58/share) vs. $5.7M ($0.30/share) YoY; R&D expenses increased to $2.6M from $0.7M reflecting expanded clinical trial sites, manufacturing, and NEO100 Phase 2a data analysis completion. The company secured UAE IND approvals for both NEO100 and NEO212 programs in June 2026. Cash position stood at $2.0M with $10M undrawn credit facility and $44.5M available under Mast Hill equity facility. Critical milestone: topline Phase 2a results for intranasal NEO100 in recurrent IDH1-mutant high-grade glioma to be presented August 12, 2026—company calls this "one of the most important clinical milestones in NeOnc's history."

The Oregon Community Foundation agreed to sell up to 738,534 shares (100% of its holding) of Jewett Cameron Trading Co. Ltd. common stock to Kotarba Partners Fund I, LP in tranches: 176,006 shares initial purchase at $1.85/share (~$326k), 176,006 optional shares at $1.85/share, and up to 386,522 additional shares at 85% of 30-day VWAP (floor $1.85, ceiling $4.00/share). Initial closing by September 30, 2026; option expires March 31, 2028. Effective date: August 6, 2026.

ARC Group International Ltd. acquired 461,354 ordinary shares and 333,333 preferred shares (47% voting power) from CEO Deng and affiliates for $8.5M cash plus $3.5M promissory note (12% annual interest, 12-month maturity) dated August 5, 2026. Transaction includes up to $5M in additional ordinary shares if Abits completes a business acquisition within 180 days, or $5M cash payment if not. Deng remains CEO; ARC gains two board seats and appoints a Chief Investment Officer.

NextEra Energy agreed to merge with Dominion Energy in an all-stock transaction (plus $360M cash) with an estimated consideration of $65.2B. Each Dominion share converts to 0.8138 NEE shares plus pro-rata cash. The combined company has pro forma assets of $391.4B and pro forma net income of $8.95B for 2025, with pro forma EPS of $3.19. Dominion shareholders and NEE shareholders must approve; regulatory approvals required from FERC, NRC, and state commissions.

Envoy Medical (market cap $12.7M) submitted the first of four modules of its modular PMA application to the FDA for its investigational fully implanted Acclaim cochlear implant on August 10, 2026. The company reported positive 12-month clinical data showing mean CNC word recognition score of 53.2% vs. 15.2% baseline (38 percentage point improvement). Q2 2026 net loss was $7.3M on $51K revenue; cash position improved to $19.7M (from $3.7M at year-end 2025) following a $30M equity raise in the period.

Beasley Broadcast Group postponed reporting Q2 2026 financial results and its earnings conference call (originally scheduled for an unspecified date, now expected by Friday, August 14, 2026) to allow additional time to finalize tax accounting treatment related to a refinancing and debt restructuring completed in Q2 2026. No specific dollar amounts, debt figures, or restructuring terms are disclosed in this announcement.

Yum China Holdings agreed to purchase all membership interests in Willow Glade Investments LLC (which holds Pizza Hut PRC assets) from Yum! Brands, Inc. for $1,200,000,000 (executed June 16, 2026). The transaction includes IP assets, brand licenses, and operational control of Pizza Hut restaurants in mainland China, with closing targeted by November 16, 2026.

National Energy Services Reunited Corp. reported Q2 2026 revenue of $520.8 million (59.1% YoY growth, 28.7% sequential), net income of $44.0 million (189.6% YoY improvement), and diluted EPS of $0.43 (168.8% YoY increase). Adjusted EBITDA reached $106.2 million (+50.5% YoY), operating cash flow was $174.0 million (+466.6% YoY), and free cash flow was $99.9 million. Net debt decreased to $99.6 million from $185.3 million at year-end 2025. No counterparties, share buybacks, or M&A transactions disclosed.

Silexion initiated a Phase 2/3 clinical trial in July 2026 for SIL204, a first-in-class RNA interference therapeutic targeting KRAS mutations in locally advanced pancreatic cancer (LAPC). The trial uses dual intratumoral and systemic delivery, with regulatory approvals received from Israel's Ministry of Health and Germany's BfArM; FDA pre-IND meeting expected early 2027. GMP clinical supply is manufactured by Catalent and Axolabs, with early human data expected Q4 2026 and U.S./EU expansion planned Q1 2027.

RHP Property GLO LLC (Ryman subsidiary) agreed to purchase the Grande Lakes resort assets in Orlando, Florida from GLO Hotel Owner LLC for $1,380,000,000, including the JW Marriott Orlando, two Ritz-Carlton hotels, and a golf club. The deal includes a $50M earnest money deposit, potential $10M additional deposit for closing extension, assumption of ~$800M existing financing, and closes by December 31, 2026. Earnest money becomes non-refundable except upon Seller default.

JBG SMITH reported Q2 2026 results with $59.2M net loss (including $44.1M impairment). Core FFO: $10.4M ($0.18/share). Major event: July 31, 2026 court judgment of $118.7M damages trebled to $356.1M in Wardman Tower litigation (company disputes liability, plans appeal). Capital activity: Sold 50% of Tysons Dulles Plaza; contributed 2200 Crystal Drive (195 units) to JV with partner contributing 70% equity for construction. Portfolio: 89.6% leased (multifamily), 78.0% (office); leverage 12.4x Net Debt/EBITDA.

Veru Inc. enrolled 239 patients (exceeding 200-patient target) in its Phase 2b PLATEAU trial testing enobosarm + semaglutide for quality weight loss in older obese patients. The company secured a clinical supply agreement with Novo Nordisk (announced June 2026) and received USPTO Notice of Allowance for a patent covering enobosarm-GLP1 combinations, expiring October 2044. Interim results expected Q1 2027; final data Q4 2027. YTD net loss improved to $15.1M ($0.68/share) vs. $24.2M ($1.65/share) prior year; cash position increased to $23.9M from $15.8M.

CECO closed acquisition of Thermon Group Holdings on June 1, 2026 for $436.9M cash (net of cash acquired). Q2 2026 orders reached $798.5M (up 191% YoY), backlog $1.819B (up 164% YoY), and revenue $285.0M (up 54% YoY). Despite Q2 GAAP net loss of $34.8M (driven by $45.5M acquisition/integration expenses and $9.5M inventory fair-value adjustments), non-GAAP net income was $21.5M (+147% YoY). Company raised full-year 2026 guidance: revenue $1.30–1.375B (prior $1.275–1.375B), Adjusted EBITDA $200–225M (prior $195–225M). Share count increased from 35.6M (Dec 2025) to 58.4M (June 2026) due to acquisition consideration paid in stock.

TPG Mortgage Investment Trust reported Q2 2026 earnings with $0.24 EAD per share (fully covering $0.24 dividend) and book value of $10.00 per share. The company announced a definitive agreement to acquire Cherry Hill Mortgage Investment Corporation (CHMI) via merger, expected to expand equity capital base, drive cost synergies, and incorporate complementary cash flows. Specific acquisition terms (purchase price, exchange ratio, timing) are not disclosed in this earnings release; further details are referenced as available in joint press release and investor presentation filed separately.

Target Hospitality reported Q2 2026 revenue of $85.5M (up 39% YoY) and Adjusted EBITDA of $18.2M (up 420% YoY), driven by its Workforce Hospitality Solutions segment. Since January 2026, the company secured over $1.4 billion in multi-year contract awards representing 9,000+ contracted beds. On July 24, 2026, Target replaced its $175M credit facility with a new $660M asset-based revolving credit facility (maturing July 2031), materially expanding liquidity. Full-year 2026 revenue guidance raised to $410-420M and Adjusted EBITDA to $85-95M.

Fox Corporation agreed on June 14, 2026 to acquire Roku Inc. for $96.00 per share in cash plus 0.9693 FOX Class A shares per Roku share, totaling preliminary estimated consideration of $23.2B ($8.6B stock, $14.6B cash). Transaction financed via $1B term loan, $11B bridge facility, and planned permanent senior unsecured debt. Pro forma shows combined entity with $42.6B assets, $20.2B equity, $22.0B revenue, and $618M net income (FY2026).

Aquestive announced positive results from human factors validation and pharmacokinetic studies for Anaphylm (dibutepinephrine) sublingual film conducted to address FDA Complete Response Letter received January 2026. Revised packaging reduced median pouch-opening time from 17 to 3 seconds; incorrect film placement dropped from 20 to 2 participants (out of 105–166); self-administered PK was comparable to clinician-administered; top-of-tongue misplacement showed clinically meaningful pharmacodynamic response. Company plans NDA resubmission in Q3 2026.

AAON delivered Q2 2026 net sales of $627.0M (+101.2% YoY), operating income of $68.9M (+192.1%), and diluted EPS of $0.68 (+257.9%). Total backlog reached $2.0B (+98% YoY), with BASX-branded backlog up 185.4% and AAON-branded backlog up 9.4%. The company raised 2026 outlook to 55%-60% net sales growth (from 40%-45%) but lowered gross margin guidance to 25%-26% (from 27%-28%) due to capacity ramp costs and price-cost timing. No specific counterparty transactions disclosed; this is operational and financial results reporting.

Sionna's SION-719 failed to meet its key efficacy endpoint in the PreciSION CF Phase 2a trial, showing only -1.0 mmol/L mean placebo-adjusted sweat chloride change (p=0.7) when added to Trikafta in 15 CF patients. The company will not advance SION-719 as an add-on to standard of care. SION-451 dual combinations (preferred: SION-451 + SION-2222) achieved safety and PK objectives in a 120-subject Phase 1 healthy volunteer trial; next steps are under evaluation. Sionna ended Q2 2026 with $268.3M in cash and plans capital-preservation measures.

MoonLake announced positive Phase 3 IZAR-1 topline results for sonelokimab 60 mg in biologic-naïve psoriatic arthritis patients at Week 16: primary endpoint ACR50 achieved at 42.1%, with strong secondary endpoints including ACR20 66.5%, MDA 41.2%, PASI90 61%. Safety profile consistent with prior studies; no new signals. Full Week 52 readout expected H1 2027. Company reported Q2 2026 cash of $537.0M (sufficient runway to mid-2028) plus $400M available debt facility with Hercules Capital.

Tenax's Phase 3 LEVEL trial of TNX-103 (oral levosimendan) for pulmonary hypertension with heart failure enrolled 241 patients (120 TNX-103, 121 placebo) and failed the primary endpoint of 6-minute walk distance improvement (3.5m difference, p=0.63). However, in prespecified subgroup analyses, patients with baseline walk distance <333m showed +26.3m improvement vs placebo (p=0.0112), and NT-proBNP fell 49% vs placebo across the overall population (p=0.0001). Company plans to request FDA Type C meeting to discuss enriched Phase 3 trial targeting sicker patients.

Varex reported Q3 FY2026 revenues of $211M (up 4% YoY), with Medical revenue $134M and Industrial revenue $77M. GAAP net income was $0.37/share; non-GAAP EPS $0.31 vs. $0.13 prior year. Q3 included a $17M tariff refund from U.S. Customs, with a $7M revenue reduction for customer reimbursements, netting ~$10M gross profit benefit. Cash declined to $99M from $155M at FY2025 end due to debt redemption/refinancing in March and increased working capital. Critically, the company cancelled its earnings call and suspended forward guidance due to the pending acquisition by Teledyne Technologies Incorporated.

Q1 FY2027 (ended June 30, 2026): Revenue $21.9M (+43% YoY), operating income $3.4M (vs. $0.8M prior year), net income $2.2M, operating cash flow $4.8M. Note: $2.7M of Q1 revenue from a customer buyout. Company reaffirmed FY2027 guidance: $80–$84M revenue, $10–$12M Adjusted EBITDA. Also repurchased >10% of outstanding shares and completed 1-for-8 share consolidation.

AbCellera announced positive Phase 2 results for ABCL635, an NK3R antagonist antibody for moderate-to-severe vasomotor symptoms (hot flashes). In a 92-patient randomized trial (46 ABCL635 600 mg SC, 46 placebo), ABCL635 achieved 83% reduction in VMS frequency vs. 33% placebo (50% placebo-adjusted difference, p<0.001) and 58% severity reduction vs. 12% placebo (46% placebo-adjusted difference, p<0.001) at week 4. Sleep and patient global impression improved significantly. Safety profile was favorable with no serious adverse events in the ABCL635 group; most common AEs were headache (28%), fatigue (13%), and injection site reaction (9%). Company plans regulatory discussions and Phase 3 advancement.